MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute ...
Earlier this month, the Departments of Labor, Health and Human Services and Treasury (the “Departments”) announced that for the foreseeable future they will not be enforcing final regulations (the ...
Reprieve Cardiovascular today announced results for its first-in-human study of the Reprieve system for the treatment of acute decompensated heart failure (ADHF). The study focused on the device’s ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...
A daily statin can reduce the risk of new-onset cardiovascular disease in people living with HIV, according to preliminary results from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE ...
-- Series B fundraise led by Deerfield Management enables scaling of pivotal clinical trial and commercial readiness activities for Reprieve® System – First patient enrolled in FASTR II study by ...
ATHENS, Greece—A device-based fluid-management system that regulates decongestion in conjunction with diuretic therapy appears safe and is able to successfully control fluid loss in patients ...
-- Late-Breaking Clinical Data Presented at the Technology and Heart Failure Therapeutics (THT) Annual Meeting Demonstrates Safety and Efficacy of the Reprieve System Compared to Optimal Diuretic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback